
Download Complimentary Report Summary
Generic drugs now account for more than 60% of all prescriptions filled in the US, and more than $60 billion worth of drugs face US patent expiration by 2011.
Use this report to build a counter-generics strategy that includes long-term, R&D-based lifecycle planning (such as new formulations and next-generation drugs) as well as frontline tactics (such as litigation and counter-promotion) - and understand how companies launch authorized generics and attempt OTC switches.
Explore primary data for a comprehensive look at current counter-generics defense:
Call Adam Bianchi at 919-433-0202 to get your own copy of "Combating Generics" today.